Go Pro
NASDAQ:FTH

Sensei Biotherapeutics Q2 2025 Earnings Report

Sensei Biotherapeutics logo
$28.00 -1.05 (-3.61%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$27.30 -0.70 (-2.50%)
As of 09/25/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sensei Biotherapeutics EPS Results

Actual EPS
-$3.91
Consensus EPS
-$6.20
Beat/Miss
Beat by +$2.29
One Year Ago EPS
N/A

Sensei Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sensei Biotherapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
9:30AM ET

Sensei Biotherapeutics Earnings Headlines

Wall Street Zen Downgrades Sensei Biotherapeutics (NASDAQ:FTH) to Sell
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
Guggenheim Begins Coverage on Sensei Biotherapeutics (NASDAQ:FTH)
See More Sensei Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sensei Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sensei Biotherapeutics and other key companies, straight to your email.

About Sensei Biotherapeutics

Sensei Biotherapeutics (NASDAQ:FTH) is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts. Sensei Biotherapeutics has conducted clinical development activities in the United States and has worked with academic and industry collaborators in advancing its oncology pipeline. The company has historically traded on Nasdaq under the symbol “SNSE”; “FTH” does not appear to be Sensei Biotherapeutics’ ticker.

View Sensei Biotherapeutics Profile